Word: flumist
(lookup in dictionary)
(lookup stats)
Dates: during 2003-2003
Sort By: most recent first
(reverse)
...they're making plans to shift supplies, if needed. But if you want a flu shot and haven't got it yet, there's no point in tarrying any longer. Healthy folks ages 5 to 49 who cannot find the vaccine can ask their doctors about a new option: FluMist, a nasal-spray vaccine. It costs $25 to $55 more than the standard shot, but several million doses of FluMist, which isn't suitable for the frail, are still available...
Hate shots? FluMist, a new alternative vaccine for the influenza viruses that send millions of Americans back to bed every winter, is administered as a nasal spray. Approved by the FDA in June for healthy people ages 5 through 49, it triggers a buildup of antibodies in the upper respiratory tract--flu's favorite point of entry. The catch: FluMist costs three to four times as much as the shot, and most health-insurance companies won't cover it. INVENTORS Hunein Maassab and MedImmune Vaccines AVAILABILITY Now, about $50 a dose TO LEARN MORE flumist.com...
...next two years. Now biotech is hot again. Since the stock market started to find its footing last July, U.S. biotech shares have risen 57%. Another bubble? Not necessarily. Many of the companies have marched steadily closer to bringing products to market. MedImmune's inhalable flu preventive FluMist was approved in mid-June. In May, Genentech's colon-cancer drug Avastin stunned scientists with its effectiveness in trials and is widely expected to be approved soon. Dozens of other products are in the works. "We're starting to see the fruits of biotech research," says Kenneth Carter, ceo of Avalon...
...biotech is hot again. Since the stock market started to find its footing last July, biotech shares have risen 57%. Another bubble? Not necessarily. Many of the companies have marched steadily closer to bringing products to market. MedImmune's inhalable flu preventive FluMist was approved two weeks ago. In May, Genentech's colon-cancer drug Avastin stunned scientists with its effectiveness in trials and is widely expected to be approved soon. Dozens of other products are in the works. "We're starting to see the fruits of biotech research," says Kenneth Carter, CEO of Avalon Pharmaceuticals, which is working...